Opinion|Videos|December 3, 2024
Examining FMT for Patients With Recurrent C Difficile infections
Author(s)Paul Feuerstadt, MD, FACG, AGAF
Key Takeaways
- FMT restores gut microbiota balance by transferring stool from healthy donors, mainly for recurrent C. difficile infections.
- Recent data shows FMT's high efficacy in preventing recurrent C. difficile, outperforming standard antibiotic treatments.
The panelist discusses how fecal microbiota transplantation (FMT) involves transferring stool from healthy donors to restore gut microbiota in patients with recurrent Clostridioides difficile infection, though safety concerns include potential pathogen transmission and careful donor screening requirements, while OpenBiome’s standardized frozen FMT preparations have helped advance accessibility but should be used according to current FDA guidance for investigational use.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Describe how FMT works and for which patients this can be used.
- What has recent data shown about the efficacy of FMT in preventing recurrent C difficile?
- What are the safety concerns when using FMT?
- Discuss the recent updates of an investigational FMT therapy from OpenBiome, and how this impacts your clinical decision-making.
Advertisement
Related to this article
A systematic review and meta-analysis found GLP-1 RAs improved liver and metabolic markers in MASLD and MASH, but long-term benefits remain unproven.
Mailed fecal immunochemical test (FIT) outreach raised CRC screening at federally qualified health centers, but gains faded by year 3.
SIRVA was rare after COVID-19 and flu shots, but COVID-19 vaccination had about 7 more cases per 100,000 doses in a study of 1.8 million.
Mucus plugs on chest CT may signal higher COPD hospitalization and death risk even without cough, and early data suggest they can be treated.
Antimicrobial resistance in bronchiectasis and cystic fibrosis varied widely in a study spanning 11 centers on 3 continents.
Experts break down the GOLD 2026 COPD guidelines, highlighting updates to diagnosis criteria, Group E risk categories, and nonpharmacologic interventions.
An economic evaluation found nontargeted hepatitis C screening in emergency departments offered the greatest health benefit at a cost-effective price.
Advertisement
Advertisement
Trending on AJMC
1
Hepatitis B Functional Cure Persists Off Treatment After Bepirovirsen
2
Health Equity & Access Weekly Roundup: November 6, 2026
3
Medicaid Cuts and Caregiving in Congress: Andy Kim
4
COPD’s Old Narrative Is Outdated, GOLD Leaders Say in 2027 Update
5